Autolus Therapeutics plc ADR (NASDAQ: AUTL) open the trading on Tuesday, with great promise as it jumped 3.21% to $2.25, before settling in for the price of $2.18 at the close. Taking a more long-term approach, AUTL posted a 52-week range of $2.16-$7.45.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 190.29% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 3.32%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 24.87%. This publicly-traded company’s shares outstanding now amounts to $266.12 million, simultaneously with a float of $236.67 million. The organization now has a market capitalization sitting at $596.85 million. At the time of writing, stock’s 50-day Moving Average stood at $3.35, while the 200-day Moving Average is $4.07.
Autolus Therapeutics plc ADR (AUTL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Autolus Therapeutics plc ADR’s current insider ownership accounts for 11.06%, in contrast to 56.28% institutional ownership.
Autolus Therapeutics plc ADR (AUTL) Earnings and Revenue Records
Autolus Therapeutics plc ADR’s EPS increase for this current 12-month fiscal period is 24.87% and is forecasted to reach -0.78 in the upcoming year.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) Trading Performance Indicators
Let’s observe the current performance indicators for Autolus Therapeutics plc ADR (AUTL). It’s Quick Ratio in the last reported quarter now stands at 13.64. The Stock has managed to achieve an average true range (ATR) of 0.21. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 59.15.
In the same vein, AUTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.21, a figure that is expected to reach -0.21 in the next quarter, and analysts are predicting that it will be -0.78 at the market close of one year from today.
Technical Analysis of Autolus Therapeutics plc ADR (AUTL)
[Autolus Therapeutics plc ADR, AUTL] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 12.17% While, its Average True Range was 0.19.
Raw Stochastic average of Autolus Therapeutics plc ADR (AUTL) in the period of the previous 100 days is set at 6.14%, which indicates a major fall in contrast to 17.31% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 61.04% that was lower than 72.20% volatility it exhibited in the past 100-days period.
